Premium
Metabolomic Signatures Of Antimycobacterial Drug Mechanisms Of Action
Author(s) -
Rhee Kyu
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.114.1
Subject(s) - antimycobacterial , metabolomics , profiling (computer programming) , computational biology , mode of action , drug , antibiotics , drug discovery , pharmacology , medicine , biology , bioinformatics , computer science , tuberculosis , toxicology , microbiology and biotechnology , mycobacterium tuberculosis , pathology , operating system
Antibiotic development remains hindered by limitations of existing knowledge and tools. Comparative systems level (omic) profiling has emerged as a powerful modality to expand our understanding and annotate the phenotypic activity of chemical compounds. Here, we report the ability of metabolomic profiling to accurately annotate and classify antimycobacterial compounds according to their target and/or mode‐of‐action. We further report that this ability can be resolved into key discriminatory subsets. These studies not only identify novel biomarkers with which to classify antitubercular compounds but more broadly serve to expand our understanding of antibiotic activity. Support or Funding Information Bill & Melinda Gates Foundation, TB Drug AcceleratorNIH/NIAID TBRU AI111143